Innate immunity and inflammation in systemic sclerosis

Current Opinion in Rheumatology

Volumn 21, Issue 6, 2009, Pages 617-622

  Lafyatis, Robert ^a   York, Michael ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Inflammasome; Interferon; Scleroderma; Toll like receptors

Indexed keywords

AUTOANTIBODY; BLEOMYCIN; CRYOPYRIN; GADOLINIUM; INTERLEUKIN 1; INTERLEUKIN 13; INTERLEUKIN 1BETA CONVERTING ENZYME; INTERLEUKIN 6; SILICON DIOXIDE; TOLL LIKE RECEPTOR; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

AUTOIMMUNE DISEASE; B LYMPHOCYTE; DENDRITIC CELL; ENZYME ACTIVATION; FIBROSIS; GENE; GENE EXPRESSION; GENE MUTATION; HUMAN; INFLAMMATION; INNATE IMMUNITY; INTERFERON RESPONSIVE GENE; LUNG FIBROSIS; MACROPHAGE; MACROPHAGE ACTIVATION; MONOCYTE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; TOXIC OIL SYNDROME;

ANTIBODIES, ANTINUCLEAR; B-LYMPHOCYTES; BLEOMYCIN; FIBROSIS; FOOD CONTAMINATION; GADOLINIUM; HUMANS; IMMUNITY, INNATE; INFLAMMATION; INFLAMMATION MEDIATORS; INTERFERONS; INTERLEUKIN-13; INTERLEUKINS; MACROPHAGE ACTIVATION; SCLERODERMA, SYSTEMIC; SILICON DIOXIDE; TOLL-LIKE RECEPTORS;

EID: 70349832889     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/BOR.0b013e32832fd69e     Document Type: Review

References (58)

1. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006; 124:783-801.
2. Lafyatis R, Marshak-Rothstein A. Toll-like receptors and innate immune responses in systemic lupus erythematosus. Arthritis Res Ther 2007; 9:222.
3. Marshak-Rothstein A. Toll-like receptors in systemic autoimmune disease. Nat Rev Immunol 2006; 6:823-835.
4. Lau CM, Broughton C, Tabor AS, et al. RNA-associated autoantigens activate B cells by combined B cell antigen receptor/Toll-like receptor 7 engagement. J Exp Med 2005; 202:1171-1177.
5. Means TK, Latz E, Hayashi F, et al. Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9. J Clin Invest 2005; 115:407-417.
6. Boule MW, Broughton C, Mackay F, et al. Toll-like receptor 9-dependent and -independent dendritic cell activation by chromatin-immunoglobulin G complexes. J Exp Med 2004; 199:1631-1640.
7. Leadbetter EA, Rifkin IR, Hohlbaum AM, et al. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature 2002; 416:603-607.
8. Tan FK, Zhou X, Mayes MD, et al. Signatures of differentially regulated interferon gene expression and vasculotrophism in the peripheral blood cells of systemic sclerosis patients. Rheumatology (Oxford) 2006; 45:694-702.
9. York MR, Nagai T, Mangini AJ, et al. A macrophage marker, Siglec-1, is increased on circulating monocytes in patients with systemic sclerosis and induced by type I interferons and toll-like receptor agonists. Arthritis Rheum 2007; 56:1010-1020.
10. Hua J, Kirou K, Lee C, Crow MK. Functional assay of type I interferon in systemic lupus erythematosus plasma and association with anti-RNA binding protein autoantibodies. Arthritis Rheum 2006; 54:1906-1916.
11. Kim D, Peck A, Santer D, et al. Induction of interferon-alpha by scleroderma sera containing autoantibodies to topoisomerase I: association of higher interferon-alpha activity with lung fibrosis. Arthritis Rheum 2008; 58:2163-2173.
12. Banchereau J, Pascual V. Type I interferon in systemic lupus erythematosus and other autoimmune diseases. Immunity 2006; 25:383-392. (Pubitemid 44354221)
13. Ronnblom L, Eloranta ML, Alm GV. The type I interferon system in systemic lupus erythematosus. Arthritis Rheum 2006; 54:408-420.
14. Czubaty A, Girstun A, Kowalska-Loth B, et al. Proteomic analysis of complexes formed by human topoisomerase I. Biochim Biophys Acta 2005; 1749:133-141.
15. Earnshaw WC, Rothfield N. Identification of a family of human centromere proteins using autoimmune sera from patients with scleroderma. Chromoso-ma 1985; 91:313-321.
16. Muro Y, Masumoto H, Yoda K, et al. Centromere protein B assembles human centromeric alpha-satellite DNA at the 17-bp sequence. CENP-B box J Cell Biol 1992; 116:585-596.
17. Krieg AM. Development of TLR9 agonists for cancer therapy. J Clin Invest 2007; 117:1184-1194.
18. Yang JM, Hildebrandt B, Luderschmidt C, Pollard KM. Human scleroderma sera contain autoantibodies to protein components specific to the U3 small nucleolar RNP complex. Arthritis Rheum 2003; 48:210-217.
19. FaticaA, Galardi S, Altieri F, Bozzoni I. Fibrillarin binds directly and specifically to U16 box C/D snoRNA. Rna 2000; 6:88-95.
20. BasergaSJ, Yang XD, Steitz JA. An intact Box Csequence in the U3snRNA is required for binding of fibrillarin, the protein common to the major family of nucleolar snRNPs. Embo J 1991; 10:2645-2651.
21. Hornung V, Barchet W, Schlee M, Hartmann G. RNA recognition via TLR7 and TLR8. Handb Exp Pharmacol 2008; 183:71-86.
22. Pisitkun P, Deane JA, Difilippantonio MJ, et al. Autoreactive B cell responses to RNA-related antigens due to TLR7 gene duplication. Science 2006; 312:1669-1672.
23. Seki E, De Minicis S, Osterreicher CH, et al. TLR4 enhances TGF-beta signaling and hepatic fibrosis. Nat Med 2007; 13:1324-1332.
24. Sugiura H, Ichikawa T, Koarai A, et al. Activation of Toll-like receptor 3 augments myofibroblast differentiation. Am J Respir Cell Mol Biol 2009; 40:654-662.
25. Meneghin A, Choi ES, Evanoff HL, et al. TLR9 is expressed in idiopathic interstitial pneumonia and its activation promotes in vitro myofibroblast differentiation. Histochem Cell Biol 2008; 130:979-992.
26. Fineschi S, Goffin L, Rezzonico R, et al. Antifibroblast antibodies in systemic sclerosis induce fibroblasts to produce profibrotic chemokines, with partial exploitation of toll-like receptor 4. Arthritis Rheum 2008; 58:3913-3923.
27. Jiang D, Liang J, Fan J, et al. Regulation of lung injury and repair by Toll-like receptors and hyaluronan. Nat Med 2005; 11:1173-1179.
28. Schaefer L, Babelova A, Kiss E, et al. The matrix component biglycan is proinflammatory and signals through Toll-like receptors 4 and 2 in macrophages. J Clin Invest 2005; 115:2223-2233.
29. Gavin AL, Hoebe K, Duong B, et al. Adjuvant-enhanced antibody responses in the absence of toll-like receptor signaling. Science 2006; 314:1936-1938.
30. Kanneganti TD, Lamkanfi M, Nunez G. Intracellular NOD-like receptors in host defense and disease. Immunity 2007; 27:549-559.
31. Gitlin L, Barchet W, Gilfillan S, et al. Essential role of mda-5 in type I IFN responses to polyriboinosinic:polyribocytidylic acid and encephalomyocardi-tis picornavirus. Proc Natl Acad Sci USA 2006; 103:8459-8464.
32. Hausmann S, Marq JB, Tapparel C, et al. RIG-I and dsRNA-induced IFNbeta activation. PLoS ONE 2008; 3:e3965.
33. Hornung V, Ablasser A, Charrel-Dennis M, et al. AIM2 recognizes cytosolic dsDNA and forms a caspase-1-activating inflammasome with ASC. Nature 2009; 458:514-518.
34. Cohen RA, Patel A, Green FH. Lung disease caused by exposure to coal mine and silica dust. Semin Respir Crit Care Med 2008; 29:651-661.
35. Rustin MH, Bull HA, Ziegler V, et al. Silica-associated systemic sclerosis is clinically, serologically and immunologically indistinguishable from idiopathic systemic sclerosis. Br J Dermatol 1990; 123:725-734.
36. Cassel SL, Eisenbarth SC, IyerSS, et al. The Nalp3 inflammasome is essential for the development of silicosis. Proc Natl Acad Sci USA 2008; 105:9035-9040.
37. Hornung V, Bauernfeind F, Halle A, et al. Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat Immunol 2008; 9:847-856.
38. Gasse P, Mary C, Guenon I, et al. IL-1 R1/MyD88 signaling and the inflam masome are essential in pulmonary inflammation and fibrosis in mice. J Clin Invest 2007; 117:3786-3799.
39. Ogura Y, Sutterwala FS, Flavell RA. The inflammasome: first line of the immune response to cell stress. Cell 2006; 126:659-662.
40. Bonniaud P, Margetts PJ, Ask K, et al. TGF-beta and Smad3 signaling link inflammation to chronic fibrogenesis. J Immunol 2005; 175:5390-5395.
41. Yang HZ, Cui B, Liu HZ, et al. Targeting TLR2 attenuates pulmonary inflammation and fibrosis by reversion of suppressive immune microenvironment. J Immunol 2009; 182:692-702.
42. Hill RH Jr, Schurz HH, Posada de la Paz M, et al. Possible etiologic agents for toxic oil syndrome: fatty acid esters of 3-(N-phenylamino)-1,2- propanediol. Arch Environ Contam Toxicol 1995; 28:259-264.
43. Posada de la Paz M, Philen RM, Schurz H, et al. Epidemiologic evidence for a new class of compounds associated with toxic oil syndrome. Epidemiology 1999; 10:130-134.
44. Bell SA, Page S, Baumgartner B, et al. Involvement of nuclear factor-kappaB in a murine model for the acute form of autoimmune-like toxic oil syndrome. Toxicol Appl Pharmacol 1999; 157:213-221.
45. Cai P, Khan MF, Kaphalia BS, Ansari GA. Immunotoxic response of oleic acid anilideand its hydrolysis products in female MRL (+/+) mice. J Immunotoxicol 2005; 2:231-236.
46. Bomford R. The adjuvant activity of fatty acid esters. The role of acyl chain length and degree of saturation. Immunology 1981; 44:187-192.
47. Wermuth PJ, Del Galdo F, Jimenez SA. Induction of the expression of profibrotic cytokines and growth factors in normal human peripheral blood monocytes by gadolinium contrast agents. Arthritis Rheum 2009; 60:1508-1518.
48. Tousova K, Vyklicky L, Susankova K, et al. Gadolinium activates and sensitizes the vanilloid receptor TRPV1 through the external protonation sites. Mol Cell Neurosci 2005; 30:207-217.
49. Fisher ER, Rodnan GP. Pathologic observations concerning the cutaneous lesion of progressive systemic sclerosis: an electron microscopic histochem-ical and immunohistochemical study. Arthritis Rheum 1960; 3:536-545.
50. Del Galdo F, Maul GG, Jimenez SA, Artlett CM. Expression of allograft inflammatory factor 1 in tissues from patients with systemic sclerosis and in vitro differential expression of its isoforms in response to transforming growth factor beta. Arthritis Rheum 2006; 54:2616-2625.
51. Duan H, Fleming J, Pritchard DK, et al. Combined analysis of monocyte and lymphocyte messenger RNA expression with serum protein profiles in patients with scleroderma. Arthritis Rheum 2008; 58:1465-1474.
52. Munder M, Eichmann K, Modolell M. Alternative metabolic states in murine macrophages reflected by the nitric oxide synthase/arginase balance: competitive regulation by CD4+ T cells correlates with Th1/Th2 phenotype. J Immunol 1998; 160:5347-5354.
53. Aliprantis AO, Wang J, Fathman JW, et al. Transcription factor T-bet regulates skin sclerosis through its function in innate immunity and via IL-13. Proc Natl Acad Sci USA 2007; 104:2827-2830.
54. Lakos G, Melichian D, Wu M, Varga J. Increased bleomycin-induced skin fibrosis in mice lacking the Th1-specific transcription factor T-bet. Pathobiology 2006; 73:224-237.
55. Yamamoto T, Nishioka K. Animal model of sclerotic skin. VI: evaluation of bleomycin-induced skin sclerosis in nude mice. Arch Dermatol Res 2004; 295:453-456.
56. Helene M, Lake-Bullock V, Zhu J, et al. T cell independence of bleomycin-induced pulmonary fibrosis. J Leukoc Biol 1999; 65:187-195.
57. Hancock A, Armstrong L, Gama R, Millar A. Production of interleukin 13 by alveolar macrophages from normal and fibrotic lung. Am J Respir Cell Mol Biol 1998; 18:60-65. (Pubitemid 128355347)
58. Hasegawa M, Fujimoto M, Kikuchi K, Takehara K. Elevated serum levels of interleukin 4 (IL-4), IL-10, and IL-13 in patients with systemic sclerosis. J Rheumatol 1997; 24:328-332.